Halozyme Thrp Stock Price, News & Analysis

Halozyme (NASDAQ: HALO) announced on December 8, 2025 that Jim Lang was elected to its Board of Directors. Mr. Lang brings over 30 years of executive experience in healthcare, life sciences, business services and data analytics.

His recent roles include CEO of EVERSANA, where he led growth through the acquisition of more than 20 companies and a merger with Waltz Health in August 2025, and former CEO of Decision Resources Group. Mr. Lang currently serves on the boards of Biovie and OptimizeRx and holds a B.S. in Electrical and Computer Engineering from the University of New Hampshire and an MBA from Tuck School of Business at Dartmouth.

Halozyme (NASDAQ: HALO) said a German court granted a preliminary injunction on Dec 4, 2025 ordering Merck to stop distributing and offering Keytruda SC in Germany for activity that would infringe European Patent No. 2 797 622 (EP 622) covering Halozyme's MDASE technology.

The order halts Merck's German launch activities within the injunction's scope; the decision is appealable and separate nullity proceedings filed by Merck in Aug 2025 are pending. Halozyme said Keytruda IV remains available and reiterated ongoing U.S. litigation alleging U.S. subcutaneous Keytruda (marketed as QLEX) infringes multiple MDASE patents.

Halozyme (NASDAQ: HALO) announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the 8th Annual Evercore Healthcare Conference. The presentation is scheduled for Tuesday, December 2, 2025 at 10:20 AM PT / 1:20 PM ET. A live audio webcast will be available on the company's Investor Relations website, and replays will be accessible for 90 days after the conference.

Halozyme (NASDAQ: HALO) completed its acquisition of Elektrofi, adding the Hypercon™ ultra‑high concentration microparticle formulation platform to its drug delivery portfolio.

Key terms: $750 million upfront, up to $900 million total with three $50 million regulatory milestones; company projects royalty revenue beginning in 2030 and up to $275 million in partner‑linked milestones from two programs expected to enter clinical development by year‑end 2026. Halozyme expects ~$55 million incremental operating expense in 2026 and estimates the deal will be less than 5% dilutive to non‑GAAP diluted EPS over the medium term.

Merus (Nasdaq: MRUS) and Halozyme (Nasdaq: HALO) announced a global non-exclusive collaboration and license agreement on November 17, 2025 to develop a subcutaneous formulation of petosemtamab using Halozyme's ENHANZE® drug delivery technology.

Merus licensed ENHANZE® for development and potential commercialization of petosemtamab, an EGFR x LGR5 bispecific antibody that is in clinical studies for multiple solid tumors including recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). Terms include an upfront payment, potential commercial and sales-based milestone payments, and low‑mid single digit royalties on net sales of the ENHANZE®-formulated product.

Halozyme (NASDAQ: HALO) announced on November 7, 2025 that Johnson & Johnson received FDA approval of DARZALEX Faspro (daratumumab and hyaluronidase-fihj) co-formulated with ENHANZE as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM). DARZALEX Faspro is described as the first and only approved treatment for HR-SMM, enabling earlier intervention before progression to active multiple myeloma.

The approval was based on the Phase 3 AQUILA study (NCT03301220) comparing DARZALEX Faspro to active monitoring. The release notes ~36,000 estimated U.S. multiple myeloma diagnoses in 2025, ~15% classified as smoldering, and an estimated 50% of HR-SMM patients progress within two years.

Halozyme (NASDAQ: HALO) priced two convertible note offerings: $650 million 0% notes due Feb 15, 2031 (2031 Notes) and $650 million 0.875% notes due Nov 15, 2032 (2032 Notes), with initial purchaser options of up to an additional $100 million for each series. Each series has an initial conversion rate equal to approximately $87.20 per share (about a 27.5% premium to the $68.39 close on Nov 6, 2025). Net proceeds are expected to be approximately $1.274 billion (or ~$1.47 billion if options exercised). The company expects to use about $182.7 million to fund capped call transactions and about $1.020 billion to repurchase outstanding 2027 and 2028 convertible notes, with an expected closing on Nov 12, 2025.

Halozyme (NASDAQ: HALO) announced a proposed offering of $650 million principal of convertible senior notes due 2031 and $650 million principal of convertible senior notes due 2032, with initial purchaser options of up to $100 million additional for each series.

The notes will be senior unsecured, accrue interest semi-annually, and mature Feb 15, 2031 and Nov 15, 2032. Conversions may be settled in cash and, at the company's election, shares of common stock. The company plans capped call transactions and expects to use proceeds for capped calls, repurchases of existing 2027 and 2028 convertible notes, and general corporate purposes.

Halozyme (NASDAQ: HALO) reported record Q3 2025 results with total revenue $354.3M (22% YoY) and royalty revenue $236.0M (52% YoY). GAAP net income was $175.2M and GAAP diluted EPS was $1.43; adjusted EBITDA was $248.2M. The company raised 2025 guidance to $1.30–1.375B total revenue, $850–880M royalties, $885–935M adjusted EBITDA, and $6.10–6.50 non-GAAP diluted EPS.

Halozyme announced a planned $750M upfront acquisition of Elektrofi with up to three $50M regulatory milestones and a CFO transition plan; share repurchases used $92.3M to buy ~1.7M shares YTD. Cash and marketable securities were $702.0M on Sept 30, 2025.